|
| | | | | | | | | | | | | | | | | |
| Name | Indication | Class | Rights | Admin | Approved | IP | Name | Indication | Class | Phase | Admin | Rights | | Price | 165 | |
| Stelara (ustekinumab) | Psoriasis | IL-12/23 mab | SGP/BMY | SC | 9/25/2009 | 2023 biosimilars? | AAV-RPGR | Retinitis Pigmentosa | | | | MGTX? | | Shares | 2598 | Q223 |
| Darzalex (daratumumab) | Multiple Myeloma | CD38 mab | GMAB | IV | 11/16/2015 | Antibody | nipocalimab | HDFN, Myopathies, CIDP | FcRn mab | III | | | | MC | 428670 | |
| Tecvayli (teclistamab) | Multiple Myeloma | BCMAxCD3 | GMAB | SC | | Antibody | aprocitentan | | ERA | III | Oral | 100%? | | Cash | 28505 | Q223 |
| Carvykti (cilta-cel) | Multiple Myeloma | BCMA CART | LGND | IV | | | AAV-CNGB3 | Achromatopsia | | II | | MGTX? | | Debt | 45602 | Q223 |
| Invega Sustenna (paliperidone palmitate) | Schizophrenia | D2 | ELN | IM | | 2016?? | JNJ-81201887/AAV-CAGsCD59 | Geographic Atrophy | | II | | | | EV | 445767 | |
| Xarelto (rivaroxaban) | Stroke prevention | Factor Xa | BAY GR | Oral | 2011 | | JNJ-67953964 (aticaprant) | Depression/Anxiety | MOR/DOR | II | Oral | | | | | |
| Imbruvica (ibrutinib) | CLL, GvHD | BTK | ABBV | Oral | 2013 | | talquetamab | Multiple Myeloma | GPRC5DxCD3 | | | | | | | |
| Remicade (infliximab) | RA, Crohn's, AS, PSA, UC, Psoriasis | TNF mab | MRK | IV | | Antibody | Ad26.preF | RSV | Vaccine | | | | | CEO: Joaquin Duato | | |
| Simponi (golimumab) | RA, PSA, AS | TNF mab | MRK/BMY | SC | | Antibody | JNJ-78278343 | CRPC | KLK2xCD3 | I | | | | CFO: Joseph Wolk | | |
| Tremfya (guselkumab) | Psoriasis | IL-23 | 1 | SC | | Antibody | JNJ-63723283 (cetrelimab) | CRPC | PD-1 | | | | | | | |
| Procrit (epoetin alfa) | Anemia | EPO | 1 | SC | | US 2013; EU expired | milvexian | Atrial Fibrillation | | | | | | | | |
| Concerta (methylphenidate) | ADHD | Amphetamine | 1 | Oral | | 2004/2017 | lazertinib (JNJ-73841937) | NSCLC | EGFR | | | | | | | |
| Invokana (canagliflozin) | T2D | SGLT2 | Mitsubishi | Oral | | | JNJ-77242113/PN-235 | Psoriasis | IL-23 | II | Oral | MRK/PTGX | | | | |
| Ponvory (ponesimod) | Multiple Sclerosis | S1P1 | IDIA | Oral | 3/18/2021 | | JNJ-42160443 (fulranumab) | OA, Bladder Pain | NGF | II | SC | 1 | | | | |
| Opsumit (macitentan) | PAH | ERA | | Oral | | | JNJ-55308942 | Bipolar | P2X7 | | | | | | | |
| Risperdal Consta | Schizophrenia | D2 | ALKS | IM | | 2013-2019 | JNJ-39588146 | Heart Failure | | II | | | | | | |
| Edurant (riplivirine) | HIV | NNRTI | 1 | Oral | | GSK, MRK, GILD | JNJ-38224342 | Allergic Rhinitis | | II | | | | | | |
| Prezista (darunavir) | HIV | Protease | 1 | Oral | | 2015 | R256918 | Obesity/Diabetes | MTTP | II | | | | | | |
| Intelence (etravirine) | HIV | NNRTI | 1 | Oral | | NCE | VAC85135 | MPNs | | | | | | | | |
| Zytiga (abiraterone) | Prostate Cancer | Testoserone | 1 | Oral | 2011 | MDVN | JNJ-80038114 | Prostate Cancer | | | | | | | | |
| Erleada (apalutamide) | Prostate Cancer | | 1 | Oral | | | JNJ-80948543 | NHL | CD79b/CD20/CD3 | | | | | | | |
| Spravato (ketamine) | Treatment-Resistant Depression | NMDA | 1 | IN | | | JNJ-75276617 | Leukemia | | | | | | | | |
| Balversa (erdafitinib) | | | | | | | JNJ-88260237 | | | | | | | | | |
| Sirturo (bedaquiline) | Tuberculosis | ATP synthase | 100%? | Oral | 12/18/2012 | | JNJ-39393406 | Schizophrenia | a7nAChR PAM | II | | | | | | |
| Rybrevant (amivantamab) | | | | | | | ASP015K | Rheumatoid Arthritis | JAK3 | II | Oral | Astellas | | | | |
| | | | | | | | JNJ-40411813 | Schizophrenia | | II | | | | | | |
| | | | | | | | JNJ-38431055 | Diabetes | | I | | | | | | |
| | | | | | | | JNJ-26854165 | Cancer | Hdm2 | I | | 1 | | | | |
| Cordis | Vision | Ethicon | DePuy | EndoSurgery | | | JNJ-40346527 | | | I | | | | | | |
| Consumer | Acquisitions | Failures | | | | | RV-568 | Asthma | Kinase | I | Inhaled | 1 | | | | |
| | | | | | | | RV-1088 | Asthma | Kinase | I | Inhaled | 1 | | | | |
| | | | | | | | CNTO5825 | | | I | IV/SC | 1 | | | | |
| | | | | | | | JNJ-26481585 | Cancer | HDAC | I | | | | | | |
| | | | | | | | JNJ-38877605 | Cancer | RTKI | I | | | | | | |
| | | | | | | | JNJ-79635322 | Multiple Myeloma | trispecific? | | | | | | | |
| | | | | | | | JNJ-64457744 | Hepatitis B | | I | | | | | | |
| | | | | | | | JNJ-17305600 | Schizophrenia | Glycine T1 reuptake | I | | | | | | |
| | | | | | | | CNTO3649 | T2D | Anti-CD3? | I | SC | 1 | | | | |
| | | | | | | | APD668 | T2D | | I | Oral | ARNA | | | | |
| | | | | | | | JNJ-19567470 | Depression/Anxiety | CRF1 antagonist | I | | | | | | |
| | | | | | | | MUNK | Neuropathic Pain | | I | Oral | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | 9/14/22: $5B buyback. Reaffirms 10.65-10.75 EPS. | | | | | | | | | |
| | | | | | | | 9/13/22: Q3 results date (10/18/22). | | | | | | | | | |
| | | | | | | | 9/6/22: Launches Octaray mapping catheter | | | | | | | | | |
| | | | | | | | 8/27/22: Darzalex GRIFFIN results presented at IMSAM | | | | | | | | | |
| | | | | | | | 8/24/22: Imbruvica approved for pediatric GvHD | | | | | | | | | |
| | | | | | | | 8/24/22: Tecvayli approved by EC | | | | | | | | | |
| | | | | | | | 8/9/22: investor conference | | | | | | | | | |
| | | | | | | | 8/4/22: EC approves new Imbruvica regimen for 1LL CLL | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | 5/11/22: Consumer Health spinout CEO announced. 2023 separation.? | | | | | | | | | |
| | | | | | | | 7/26/19: CHMP positive opinion for Stelara for UC | | | | | | | | | |
| | | | | | | | 7/25/19: Phase III ponesimod RMS results | | | | | | | | | |